Healthcare Equipment and Supplies
Company Overview of Intersect ENT Inc.
Sinexus, Inc., a medical device company, engages in developing therapies for ear, nose, and throat physicians in the United States. It develops a therapeutic device for the treatment of chronic sinusitis. Sinexus, Inc. was founded in 2003 and is based in Palo Alto, California.
1049 Elwell Court
Palo Alto, CA 94303
Founded in 2003
Key Executives for Intersect ENT Inc.
Chief Executive Officer and President
Compensation as of Fiscal Year 2013.
Intersect ENT Inc. Key Developments
Intersect ENT Inc. Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-14-2014 07:30 AM
Dec 9 13
Intersect ENT Inc. Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-14-2014 07:30 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States. Speakers: Lisa D. Earnhardt, Chief Executive Officer and President.
Intersect ENT Inc. Presents at MedTech Investing Conference, May-08-2013 11:35 AM
May 5 13
Intersect ENT Inc. Presents at MedTech Investing Conference, May-08-2013 11:35 AM. Venue: Graves 601 Hotel, 601 First Avenue North, Minneapolis, MN 55401, United States. Speakers: Lisa D. Earnhardt, Chief Executive Officer and President.
Intersect ENT Inc. Initiates U.S. Clinical Study of a Novel In-Office Treatment for Chronic Sinusitis Patients
Jan 31 13
Intersect ENT Inc. announced the start of RESOLVE, a prospective, randomized, blinded, multi-center clinical trial to study the use of the company's newest steroid delivery implant for patients with chronic sinusitis. Intersect ENT's new product, which is placed during a routine physician office visit, is designed as a treatment alternative for patients with recurrent sinus obstruction. Like the company's PROPEL(TM) and PROPEL(TM) mini implants used in the operating room setting to improve surgical outcomes, the product being studied releases mometasone furoate, an advanced steroid with anti-inflammatory properties, directly into the sinus lining to resolve inflammation. The product has more radial strength than the PROPEL products in order to dilate the re-obstructed sinus, and releases the steroid over a longer period of time to keep inflammation at bay. The RESOLVE Study will enroll 100 patients, at up to 20 U.S. sites, who suffer from chronic sinusitis due to recurrent sinus obstruction so severe that revision surgery is warranted. Chronic sinusitis is a condition in which patients' sinuses become swollen and inflamed, leading to difficulty breathing, facial pain or headache, and reduced sense of smell and taste. The condition is common, affecting 31 million people in the U.S., and greatly impacts quality of life. Chronic sinusitis often requires a complex combination of surgical and medical treatments. Each year, 500,000 patients undergo sinus surgery to treat the condition. Although sinus surgery is effective, majority of patients experience recurrent symptoms within the first year; as many as 25% then undergo revision surgery due to recurrent obstruction of the sinus cavity. The RESOLVE study is designed to evaluate Intersect ENT's implant in patients with polyps, which is the most challenging chronic sinusitis patient population. Polyps recur in up to 60% of patients following endoscopic sinus surgery (ESS) and are the cause for revision surgery. Co-Principal Investigators for the study are Keith D. Forwith, M.D., Ph.D. of Advanced ENT & Allergy in Louisville, KY, and Joseph Han, M.D., director of Rhinology and Endoscopic Sinus/Skull Base Surgery and professor at the Eastern Virginia Medical School.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|